Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia

Gina Ma; Yi Wang; Tahmeena Ahmed; Ann Leslie Zaslav; Laura Hogan; Cecilia Avila; Masayuki Wada; Huda Salman

doi:10.1016/j.lrr.2018.03.002

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia

Gina Ma
, Yi Wang
, Tahmeena Ahmed
, Ann Leslie Zaslav
, Laura Hogan
, Cecilia Avila
, Masayuki Wada
, Huda Salman

iCell Gene Therapeutics LLC
Stony Brook University

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases.

Original language	English
Pages (from-to)	42-44
Number of pages	3
Journal	Leukemia Research Reports
Volume	9
DOIs	https://doi.org/10.1016/j.lrr.2018.03.002
State	Published - 2018

Keywords

Acute myeloid leukemia
Chimeric antigen receptors
Immunotherapy
Mixed phenotype acute leukemia
T cells

Access to Document

10.1016/j.lrr.2018.03.002

Cite this

@article{031c972895524fc3beab2484e6d8a656,

title = "Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia",

abstract = "Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases.",

keywords = "Acute myeloid leukemia, Chimeric antigen receptors, Immunotherapy, Mixed phenotype acute leukemia, T cells",

author = "Gina Ma and Yi Wang and Tahmeena Ahmed and Zaslav, \{Ann Leslie\} and Laura Hogan and Cecilia Avila and Masayuki Wada and Huda Salman",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2018",

doi = "10.1016/j.lrr.2018.03.002",

language = "English",

volume = "9",

pages = "42--44",

journal = "Leukemia Research Reports",

issn = "2213-0489",

}

TY - JOUR

T1 - Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia

AU - Ma, Gina

AU - Wang, Yi

AU - Ahmed, Tahmeena

AU - Zaslav, Ann Leslie

AU - Hogan, Laura

AU - Avila, Cecilia

AU - Wada, Masayuki

AU - Salman, Huda

PY - 2018

Y1 - 2018

N2 - Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases.

AB - Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases.

KW - Acute myeloid leukemia

KW - Chimeric antigen receptors

KW - Immunotherapy

KW - Mixed phenotype acute leukemia

KW - T cells

UR - https://www.scopus.com/pages/publications/85045192515

U2 - 10.1016/j.lrr.2018.03.002

DO - 10.1016/j.lrr.2018.03.002

M3 - Article

AN - SCOPUS:85045192515

SN - 2213-0489

VL - 9

SP - 42

EP - 44

JO - Leukemia Research Reports

JF - Leukemia Research Reports

ER -

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia